Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
BioSpace18h
Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech
Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...
Fierce Biotech18h
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...
Novo Nordisk expands discounted Wegovy to all cash-paying US customers
Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a ...
Eli Lilly Shares Are Up Today: What's Going On?
Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...
Fierce Pharma17h
Novo Nordisk offers cheaper Wegovy for all cash-paying patients at retail pharmacy
Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...
Eli Lilly (LLY) Leads India’s Weight-Loss Drug Race with Mounjaro
Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover ...
Eli Lilly launches weight-loss drug Mounjaro in India at $50 for 5 mg vial, beating Novo Nordisk
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...